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Abstract
Background:  The peptide hormone ghrelin has many important physiological and
pathophysiological roles, including the stimulation of growth hormone (GH) release, appetite
regulation, gut motility and proliferation of cancer cells. We previously identified a gene on the
opposite strand of the ghrelin gene, ghrelinOS (GHRLOS), which spans the promoter and
untranslated regions of the ghrelin gene (GHRL). Here we further characterise GHRLOS.
Results: We have described GHRLOS mRNA isoforms that extend over 1.4 kb of the promoter
region and 106 nucleotides of exon 4 of the ghrelin gene, GHRL. These GHRLOS transcripts initiate
4.8 kb downstream of the terminal exon 4 of GHRL and are present in the 3' untranslated exon of
the adjacent gene TATDN2 (TatD DNase domain containing 2). Interestingly, we have also identified
a putative non-coding TATDN2-GHRLOS  chimaeric transcript, indicating that GHRLOS  RNA
biogenesis is extremely complex. Moreover, we have discovered that the 3' region of GHRLOS is
also antisense, in a tail-to-tail fashion to a novel terminal exon of the neighbouring SEC13 gene,
which is important in protein transport. Sequence analyses revealed that GHRLOS is riddled with
stop codons, and that there is little nucleotide and amino-acid sequence conservation of the
GHRLOS gene between vertebrates. The gene spans 44 kb on 3p25.3, is extensively spliced and
harbours multiple variable exons. We have also investigated the expression of GHRLOS and found
evidence of differential tissue expression. It is highly expressed in tissues which are emerging as
major sites of non-coding RNA expression (the thymus, brain, and testis), as well as in the ovary
and uterus. In contrast, very low levels were found in the stomach where sense, GHRL derived
RNAs are highly expressed.
Conclusion: GHRLOS RNA transcripts display several distinctive features of non-coding (ncRNA)
genes, including 5' capping, polyadenylation, extensive splicing and short open reading frames. The
gene is also non-conserved, with differential and tissue-restricted expression. The overlapping
genomic arrangement of GHRLOS with the ghrelin gene indicates that it is likely to have interesting
regulatory and functional roles in the ghrelin axis.
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Background
Ghrelin, a hormone with many physiological and patho-
physiological roles, was initially described as the endog-
enous ligand for the growth hormone secretagogue
receptor (GHSR 1a), through which it stimulates the
release of growth hormone from the anterior pituitary [1].
Ghrelin is primarily produced in the stomach and plays a
key role in regulating appetite, gut motility and energy
balance [2-6]. Ghrelin is also an autocrine factor in a
number of tissues, as it regulates insulin release and has
therapeutic potential for inflammatory diseases, heart dis-
ease, cancer cachexia, diabetes mellitus and obesity [7].
Despite the importance of ghrelin in a range of physiolog-
ical systems and pathophysiological conditions, little is
known about the regulation of ghrelin synthesis and
secretion. We previously identified a gene on the opposite
strand of the ghrelin gene, ghrelinOS (GHRLOS), which
spans the promoter and untranslated regions of the ghre-
lin gene (GHRL) [8]. However, the genomic structure,
expression pattern and potential function of GHRLOS
remains to be investigated. It is not known whether GHR-
LOS  RNA species with open reading frames exist, or
whether GHRLOS is a non-coding RNA gene.
There is strong support for the hypothesis that antisense
transcripts provide a widespread and important mecha-
nism for the regulation of the human genome [9,10]. Our
understanding of the genome is currently undergoing a
paradigm shift, as a previously hidden and complex layer
of antisense and non-coding RNAs is emerging, which
controls gene transcription and translation through a
diverse range of mechanisms [11]. Much phenotypic
diversity between humans and other species is likely to be
due to regulation by RNA [12].
In this study, we examined the genomic structure and
organisation of GHRLOS. We have found that GHRLOS
spans approximately 44 kb of genomic DNA and tran-
scribes long, 5' capped, polyadenlyated RNA species that
are extensively spliced and differentially expressed. High
levels of GHRLOS expression occur in the emerging non-
coding RNA tissues, the brain, testis and thymus. We have
also examined GHRLOS RNA species in silico, revealing
that GHRLOS is a candidate non-coding RNA gene. These
data provide a strong basis for further functional studies
to determine whether GHRLOS plays a role in the regula-
tion of ghrelin gene expression.
Results
Characterisation of GHRLOS start sites and alternative 
splicing
An initial aim of this study was to characterise GHRLOS in
a range of tissues. As we have previously demonstrated the
expression of GHRLOS mRNA transcripts in the human
stomach [8], we performed 5' RLM-RACE (RNA ligase
mediated rapid amplification of cDNA ends) on this tis-
sue. Unexpectedly, we identified a number of new exons
(exon I-III) [GenBank:EU789528, EU789529, and
EU789530] that are 2.5 to 4.8 kb upstream of the previ-
ously reported GHRLOS  transcription start sites [8] in
exon 4* (4*a-c). To simplify the numbering of GHRLOS
exons, the previously reported [8] exons 4*, 2**, 2* and -
1* have been renamed exon 1 to 4, respectively; while the
exons upstream of the reported start sites in exon 1 are
denoted by Roman numerals (I-III). Importantly, in the
GHRLOS variants demonstrated via 5' RLM-RACE, exon 1
is extended, with a 106 nt region (exon 1d, hereafter
termed exon 1) overlapping exon 4 of the ghrelin gene
(see [Additional file 1]). The novel first exon, exon I, is 51
bp in size (Fig. 1) and overlaps the 3' untranslated region
of the adjacent gene, TATDN2 (TatD DNase domain con-
taining 2, also known as hypothetical protein KIAA0218)
[13]. This gene initiates on the same DNA strand as GHR-
LOS, approximately 32,000 base pairs upstream of the 51
bp exon I of GHRLOS.
In order to determine the polyadenylation site(s) of GHR-
LOS transcripts, 3' RACE and inverse PCR were conducted
using normal stomach and prostate tissues, the RWPE-1
prostate cell line and the PC3 prostate cancer cell line
(which is derived from prostate cancer cells that have
metastasised to the bone). We obtained 3' RACE clones
from the PC3 prostate cancer cell line, which demon-
strated a 1.4 kb exon 4a and a 1.1 kb exon 4b, with the
putative polyadenylation signal AAATTA [Gen-
Bank:EU789531, and EU789532] (Fig. 1). The 3' RACE
data matches a number of Expressed Sequence Tags (ESTs)
from subchondral bone [GenBank:BM991802], foetal
liver [GenBank:AI056187], pooled liver and spleen [Gen-
Bank:BX118778; R01027], Wilms' tumour (a paediatric
cancer of the kidney) [GenBank:AI174574], pooled brain
cancers [GenBank:AI863058] and high grade serous carci-
noma of the uterus [GenBank:AI289483]. Moreover, we
performed uncapped inverse PCR, and sequencing of
amplicons from the PC3 cell line revealed a 90 bp exon I
and exon 4 sequence with a 3' end differing by less than
20 base pairs when compared to the 3' RACE and reported
ESTs [GenBank:EU789533]. Interestingly, the putative 3'
end of exon 4 corresponds to publicly available Affyme-
trix Human Exon 1.0 ST array data (Exon Cluster ID
183613). Furthermore, all of the amplicons that we
obtained were followed by a stretch of adenosines at the
3' ends that are not present in the genomic sequence. We,
therefore, concluded that we had reached a genuine 3' end
of GHRLOS.
Complex pattern of GHRLOS variant exon expression
In order to examine the size and tissue distribution of
GHRLOS transcripts, we performed Northern blot analy-
sis of mRNA from human stomach and 12 normal,BMC Molecular Biology 2008, 9:95 http://www.biomedcentral.com/1471-2199/9/95
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Mapping of GHRLOS transcript 5' and 3' ends Figure 1
Mapping of GHRLOS transcript 5' and 3' ends. Relative positions of the 5' and 3' ends of GHRLOS transcripts were 
derived from RACE, inverse PCR and cDNA primer walking RT-PCR experiments, as well as from publically available data 
from EST databases, Affymetrix exon arrays and CAGE tags. TATDN2 exons are shown as white boxes, GHRLOS exons as black 
boxes, introns as horizontal lines. Size (bp) of selected exons are shown above each exon. All known 3' ends of GHRLOS tran-
scripts contain the same polyadenylation signal. Poly(A) tails are represented by AAAA. Cap-analysis gene expression (CAGE) 
tags are indicated by arrows, and CAGE-aided cDNA primer walking amplicons are displayed below the arrows. Not drawn to 
scale.BMC Molecular Biology 2008, 9:95 http://www.biomedcentral.com/1471-2199/9/95
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human tissues. With a riboprobe designed to span exons
I, II, 1 and 2 of GHRLOS, a weak, smeared signal ranging
from approximately 1.0 to 2.0 kb in size was observed in
the human stomach upon a lengthened exposure time
(data not shown). A riboprobe spanning exon 1 alone (a
region common to all GHRLOS RNA isoforms) resulted in
signals ranging from 1.0 to 5.5 kb in size in the pancreas,
prostate, salivary gland and thymus (Fig. 2). Upon longer
exposure times, a smear in the 1.0 to 5.5 kb range was seen
in all tissues, except for peripheral blood leukocytes and
urinary bladder (data not shown). This suggests that GHR-
LOS  is a fully processed transcript consisting of many
mRNA isoforms.
GHRLOS exons are highly polymorphic
The RACE, inverse RT-PCR and Northern blotting experi-
ments indicate that GHRLOS is extensively spliced and
that isoforms range greatly in size (from approximately
1.0–5.5 kb). To examine the alternative splicing pattern of
GHRLOS in greater detail, we performed RT-PCR using a
Northern blot of poly(A)+ RNA from normal, human tissues with strand-specific, DIG-labelled riboprobe Figure 2
Northern blot of poly(A)+ RNA from normal, human tissues with strand-specific, DIG-labelled riboprobe. 
Northern blot of 2 μg poly(A)+ RNA from 12 normal tissues (OriGene) probed for exon 1, which is an exon common to all 
known GHRLOS mRNA isoforms (top panel). The position of the RNA size markers is indicated (RNA Millennium Markers, 
OriGene). A pound mark (#) indicates a putative 1.7–1.8 kb (approximately 2.0 kb with polyadenylation tail) full-length tran-
script in the prostate, as deduced from RLM-RACE and RT-PCR experiments. Several other transcripts 1–5.5 kb in size could 
be seen. The same membrane was stripped and hybridized with a β-actin cRNA probe as a loading control (bottom panel).BMC Molecular Biology 2008, 9:95 http://www.biomedcentral.com/1471-2199/9/95
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range of human tissues and cell lines. We used a forward
primer common to exon Ia (identified via 5' RLM-RACE)
and a reverse primer in a region common to exons 4a and
b. Sequence analysis indicated that, with the exception of
exons 1 and 4, which are common to all known GHRLOS
isoforms, GHRLOS exons are highly polymorphic in size
and exon skipping occurs frequently. A representative
amplicon banding pattern is shown in [Additional File 2].
The highly variable splicing pattern revealed by RT-PCR is
consistent with the diffuse and broad signal which we
detected by Northern blotting. In total we obtained 13 dif-
ferent  GHRLOS  splice variants (Fig. 3). Analysis using
GMAP, a genomic mapping and alignment program for
mRNA and EST sequences [14], indicated that all GHR-
LOS  exons are flanked by canonical splice donor and
acceptor sites (GT/AG), except for exons 3a and 3c where
the splice junction is the common non-canonical splice
pair GC/AG [15]. GHRLOS exons and introns identified
are listed in [Additional File 3].
Extending the known length of GHRLOS
Northern blotting demonstrated GHRLOS transcripts 1–
5.5 kb in size, however, further RT-PCR and 3' RACE anal-
ysis with a number of different primer combinations
failed to reveal GHRLOS transcripts larger than 2 kb (data
not shown). For this reason, we hypothesised that the
ghrelin antisense gene may extend further upstream.
Capped RLM-RACE of stomach tissue and uncapped
inverse PCR of the PC3 prostate cancer cell line (Fig. 1)
indicated that a GHRLOS promoter (exon I) was present
at the very end of the 2 kb 3' untranslated exon 8 of
TATDN2. Moreover, we discovered that multiple Cap
Analysis of Gene Expression (CAGE) tags are clustered
approximately 1.5 kb upstream of the GHRLOS transcrip-
tion start sites found via 5' RLM-RACE. CAGE tags are an
average of 20–21 nucleotides and are produced by large-
scale sequencing of concatemers derived from the 5' ends
of capped mRNA [16,17]. The CAGE method, therefore,
detects the most 5' site of the mRNA transcripts (the tran-
scription start site) and gives an unbiased and compre-
hensive picture of the positions and usage of transcription
start sites [18]. To confirm if this region belongs to GHR-
LOS, we employed nested RT-PCR using thymus tissue,
foetal brain tissue and Hep G2 hepatocarcinoma cell line
cDNA (with RNA reverse transcribed using oligo(dT)
primers). The forward primers were present immediately
downstream of the CAGE tag cluster (which is 1.5 kb
upstream of the 51 bp exon I of GHRLOS) and the reverse
primers spanned exon 1 (which is common to all known
GHRLOS  variants). Sequence analysis revealed several
novel exon I variants, which were approximately 1601 bp,
994 bp and 526 bp in length. All of these variants spliced
into the expected acceptor site of the 106 bp exon 1 (Fig.
1 and [Additional File 4]). The end of the 1601 bp exon I
(termed exon Ib) spanned the 51 bp exon I (exon Ia) iden-
tified via capped RLM-RACE of the stomach, while the
other exons (Ic-d) employed different upstream donor
sites, suggesting that they are alternative first exons. The
data demonstrate that there are at least two first GHRLOS
exon regions in the untranslated region of TATDN2. This
suggests that the GHRLOS  promoter is a broad-type,
TATA-less promoter that initiates transcription at many
sites [19].
The length of GHRLOS  transcripts initiating in exon I
(present in the 3' UTR of TATDN2) is 1.3–3.6 kb, corre-
sponding in size to the Northern data. However, the
potential identity of the approximately 5.5 kb transcript
seen in the Northern blot with a full-length, 106 nt exon
1 probe (Fig. 2) was not determined. After prolonged
exposure of the Northern blot, the 5.5 kb transcript was
observed in all tissues except the urinary bladder and
uterus (data not shown). TATDN2 is only approximately
1 kb upstream of exon II and 4.5 kb from exon 1 of GHR-
LOS, suggesting that transcription-induced chimaeras
(TICs) may be generated [20] and give rise to large GHR-
LOS transcripts. Because TICs must contain a first exon of
the upstream gene [20], we employed primers in exon 2
(immediately after the start codon) of TATDN2 and exon
1 of GHRLOS (which was also the sequence of our North-
ern riboprobe). Using nested RT-PCR (on cDNA reverse
transcribed using oligo(dT) primers), we isolated a 2831
bp TATDN2-GHRLOS amplicon from the thymus [Gen-
Bank:EU789553] (Fig. 4). This transcript has canonical
splice donor and acceptor sites (GT/AG) and splices into
the expected acceptor site of the 106 bp exon 1. This vari-
ant harbour significant open reading frames correspond-
ing to the TATDN2 protein, but contains alternative exons
and a premature termination codon more than 50 bp
upstream of the final coding exon 7 of TATDN2 (Fig. 4).
This is likely to result in degradation of the mRNA by non-
sense-mediated RNA decay (NMD), a surveillance mecha-
nism that detects and degrades mRNA that may encode
truncated proteins with dominant-negative or deleterious
gain-of-function activities [21].
We have identified several novel GHRLOS  transcripts.
This includes overlapping GHRLOS transcripts initiating
in the TATDN2 3' UTR and putative transcription-induced
chimaeras of TATDN2  and  GHRLOS. These findings
extend the previously reported length of GHRLOS by ~37
kb. We propose that GHRLOS harbour several promoters
with start sites in exon 1 (of GHRLOS), and in the 3' UTR
and the first exon of TATDN2.
Results of in silico analysis indicate that GHRLOS is a 
non-coding RNA gene
Sequence analysis of GHRLOS  (excluding the putative
TATDN2-GHRLOS transcription-induced chimaeras that
are likely to result in nonsense mediated decay) revealsBMC Molecular Biology 2008, 9:95 http://www.biomedcentral.com/1471-2199/9/95
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Complex pattern of GHRLOS variant exon expression Figure 3
Complex pattern of GHRLOS variant exon expression. GHRLOS transcripts A to M were demonstrated by RT-PCR, 
while the 5' end (exon I) and 3' end (exon 4) were determined by RACE, inverse PCR and by examining publically available 
Affymetrix exon array data and expressed sequence tag (EST) data. Exons are represented as boxes, introns as horizontal lines 
and sizes (bp) are indicated below each exon. The size of exon 4a is listed as 1377–1388 and corresponds to a transcript which 
is polyadenylated 20–30 bp from the same polyadenylation signal (data not shown). Exon 4b harbours the same polyadenlation 
site, but is 5' truncated (250 bp). GhrelinOS variants A to M have been deposited to GenBank: A-F, stomach [Gen-
Bank:EU789534, EU789535, EU789536, EU789537, EU789538, and EU789539]; G-H, prostate [GenBank:EU789540, and 
EU789541]; I, foetal brain [GenBank:EU789542]; J-M, heart [GenBank:EU789543, EU789544, EU789545, and EU789546].BMC Molecular Biology 2008, 9:95 http://www.biomedcentral.com/1471-2199/9/95
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that GHRLOS transcripts do not harbour protein coding
potential, but rather have several features of non-coding
RNA genes. GMAP analysis showed that GHRLOS spans
approximately 44 kb on 3p25.3 (data not shown). The
Mulan sequence conservation profile for the human and
putative vertebrate GHRLOS orthologues indicated that
most GHRLOS exons (I, II, III, 2, 3) are not highly con-
served compared to the putative mouse and rat ortho-
logues (Fig. 5). The 106 bp exon 1 (which spans exon 4 of
the ghrelin gene) and approximately 90 bp of the 1.4 kb
exon 4 (which spans exon -1 of the ghrelin gene) are con-
served, however [8]. RT-PCR experiments revealed no evi-
dence for antisense transcription from exon I to exon 1 (of
GHRLOS) in the mouse (data not shown), suggesting that
ghrelin antisense transcription (at these specific locations)
may not be conserved. Furthermore, there is very low
sequence similarity between the chicken, frog, opossum
and human GHRLOS  sequences (Fig. 5). Interestingly,
exons II, 2 and 3 appear to be highly conserved between
human and dog [Additional File 5], with 70–75% homol-
ogy for exons 2 and 3. However, no significant open read-
ing frames (ORFs) are conserved between dog and human
GHRLOS sequence (data not shown). Taken together, this
suggests that GHRLOS has evolved rapidly and may be
unique to primates.
Our study suggests that GHRLOS is a non-coding RNA. In
silico translation revealed that the heterogeneous GHRLOS
RNAs contain multiple stop codons, resulting in lack of
extensive reading frames, and the putative ORFs do not
span conserved regions (data not shown). Moreover, no
significant sequence similarity to any known proteins was
observed (data not shown). Finally, screening of GHRLOS
sequence against a reference collection of repeats (Rep-
basE) using CENSOR [22] identified a 203 bp overlap of
exon 4 with the extinct 224 bp MIR3 SINE element, which
is present in all vertebrates [23] (Fig. 5). Interestingly, the
presence of repeat elements in exons of non-coding RNAs
has been reported previously [24-27]
The GHRLOS terminal exon 4 and a putative SEC13 exon 
overlap in an antisense manner
We have discovered that exon 4 of GHRLOS is also on the
opposite strand of a novel terminal exon of the neigh-
Identification of a TATDN2-GHRLOS chimaeric transcript by nested RT-PCR Figure 4
Identification of a TATDN2-GHRLOS chimaeric transcript by nested RT-PCR. (A) Overview of the gene structures 
of TATDN2 (orange) and GHRLOS exons (blue). TATDN2 exon 8 contains first exons of GHRLOS and is therefore shown in 
orange and blue. Exons are represented as boxes, introns as horizontal lines and sizes (bp) are indicated below each exon. A 
TATDN2 CpG island is shown as a green box. The location of RT-PCR primers employed to detect chimaeras are shown below 
each exon as arrows. The reported 761 amino acid TATDN2 open reading frame (encoded by [GenBank:NM_014760]) is 
shown as a straight line (M = initiating methionine; * = stop codon). A chimaeric TATDN2-GHRLOS transcript, its open reading 
frame and locations of a premature stop codon (*) is shown. Not drawn to scale. (B) Ethidium bromide stained agarose gel of 
nested RT-PCR product for the TATDN2-GHRLOS chimaera. Arrows indicates the amplicon schematically displayed in (A). M = 
1 kb DNA Ladder (NEB).BMC Molecular Biology 2008, 9:95 http://www.biomedcentral.com/1471-2199/9/95
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bouring SEC13 gene in a tail-to-tail, 3' to 3', fashion (Fig.
6A) [Additional File 6]. SEC13 plays an important role in
protein transport and is a component of the COPII com-
plex [28,29]. BLAST analysis identified a brain tumour
EST [GenBank:BF931280] [30], which contains exon 7
and 8 of SEC13, as well as 206 bp sequence corresponding
to a novel exon 9b of SEC13 10.7 kb upstream of exon 8.
We verified the expression of this EST by RT-PCR (using
cDNAs reverse transcribed with oligo(dT) primers) (Fig.
6B) and by sequencing [GenBank:EU789555]. We have
named this SEC13  variant, SEC13-tentative (SEC13-T).
SEC13-T may encode a 372 amino acid protein. The first
285 amino acids are identical to SEC13, while the normal
C-terminal 37 amino acids have been replaced by 87
amino acids encoded by the alternative terminal exon 9b
(Fig. 6C and 6D). The putative C-terminal-coding exon of
the SEC13-T isoform appears to be conserved only in pri-
mates (data not shown). Therefore SEC13-T alternative
splicing is likely to be human-specific or primate-specific.
Mulan sequence conservation profile for vertebrate GHRLOS loci Figure 5
Mulan sequence conservation profile for vertebrate GHRLOS loci. The horizontal axis displays the input sequence 
from human (UCSC hg18), chicken [UCSC galGal3], frog [UCSC xenTro2], opossum [UCSC monDom4], mouse [UCSC 
mm9], rat [UCSC rn4], dog [UCSC canFam2], rhesus macaque [UCSC rheMac2], and chimpanzee [UCSC PanTro2] GHRLOS 
loci. Evolutionary conserved regions (ECRs, > 70% identity; ≥ 99 bp) are depicted as dark red bars above each pairwise align-
ment. Exons (blue), intergenic elements (red) and intron sequence (pink) are marked and the vertical axis shows the percent 
similarity of vertebrate GHRLOS orthologues to the human sequence. GHRLOS exon numbers are shown. A transposable ele-
ment in exon 4 (MIR3#SINE/MIR) is shown above exon 4.BMC Molecular Biology 2008, 9:95 http://www.biomedcentral.com/1471-2199/9/95
Page 9 of 22
(page number not for citation purposes)
GHRLOS is expressed in many tissues and cell lines and 
the level of expression shows great variability
RT-PCR analysis (with primers spanning GHRLOS termi-
nal exons) and Northern blotting (which is only suitable
for high copy number transcripts) demonstrated that the
size of GHRLOS transcripts is highly variable, resulting in
significant transcript heterogeneity. We, therefore,
employed a quantitative, real-time RT-PCR approach in
order to more precisely gauge the expression of GHRLOS
in a range of tissues and cell lines. As the number of alter-
natively spliced GHRLOS transcripts makes it impossible
to generate real-time RT-PCR primers that are unique to
GHRLOS overlaps a putative SEC13 isoform, SEC13-T, in an antisense manner Figure 6
GHRLOS overlaps a putative SEC13 isoform, SEC13-T, in an antisense manner. (A) Diagrammatic representation of 
GHRLOS, SEC13, and a novel SEC13 isoform, named SEC13-tentative (SEC13T). SEC13-T contains a novel terminal exon 9, 
termed exon 9b, which overlaps exon 4 of GHRLOS in an antisense manner. In the figure, exon 9b of SEC13-T is dotted to indi-
cate that its complete 3' end has not been verified. Exons are represented as boxes and introns as horizontal lines. The loca-
tions of the primers employed to verify the SEC13T variant are displayed as arrows. SEC13 and SEC13-T GenBank accession 
numbers are shown. (B) Ethidium bromide stained agarose gel showing the verification of a SEC13-T EST [GenBank:BF931280] 
transcription by RT-PCR in prostate (RWPE-1 and RWPE-2) and prostate cancer derived cell lines (DU-145, PC3, LNCaP). 
NTC = no template control (water). M= DNA Molecular Weight Marker VI (Roche). Primer locations are depicted in (A). A 
231 PCR fragment was amplified and sequenced, confirming the EST. (C) RNA and amino acid sequence of exon 9b of SEC13-
T. Additional downstream sequence corresponding to 18 in-frame codons and a stop codon is highlighted in green. (D) SEC13 
and SEC13-T amino acid sequences. SEC13 encodes a 322 AA protein with six WD-40 repeats (also known as WD or beta-
transducin repeats) are underlined. Amino acid sequence of SEC13 which is different to SEC13T is shown in blue. SEC13-T may 
encode a 372 AA protein: Its first 285 amino acids are identical to SEC13 and the normal C-terminal 37 amino acids have been 
replaced by 87 amino acids (shown in red) encoded by exon 9b.BMC Molecular Biology 2008, 9:95 http://www.biomedcentral.com/1471-2199/9/95
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each splice variant (data not shown), a strand-specific
quantitative RT-PCR assay with primers in exon 4 (which
is common to all GHRLOS  variants) was designed to
detect total GHRLOS RNA expression (Fig. 7A).
The level of total GHRLOS transcript expression varied
greatly in different human tissues, with high levels in the
thymus, testis, foetal brain, uterus, cerebellum, ovary, thy-
roid, and whole brain. Very low levels of total GHRLOS
RNA expression were detected in the stomach, foetal liver
and pancreas (Fig. 7B). In the thymus the level of expres-
sion was approximately 133 fold higher than in the stom-
ach (P < 0.01) and 110-fold higher than in the foetal liver
(P < 0.01). Furthermore, the level of expression in the
adult liver was 9-fold higher than in the foetal liver (P <
0.05), indicating differential expression according to
developmental stage in this tissue. The level of GHRLOS
in the foetal brain was two-fold higher than the adult
brain, but this was not statistically significant (P > 0.05).
Expression of GHRLOS in a number of continuous cell
lines was also examined using real-time RT-PCR (Fig. 7C).
Levels of GHRLOS expression in the U-937 (Non-Hodg-
kin's lymphoma) and SW1353 (chondrosarcoma) cell
lines were similar to the cerebellum, uterus, foetal brain,
testis and thymus. High levels of expression were
observed in the HEK293 human embryonic kidney cell
line and in the CaCo-2 (colon adenocarcinoma), SAOS-2
(osteosarcoma), U-87 MG and U251-MG (glioblastoma),
OVCAR-3 (ovarian adenocarcinoma) and Hep G2 (hepa-
tocarcinoma) cancer cell lines. It is interesting to note that
multiple Hep G2 CAGE tags have been identified in the
exon I region of GHRLOS (see [Additional File 4]). GHR-
LOS RNA appears to be significantly upregulated in the
Hep G2 cell line compared to adult and foetal liver (P <
0.05) (Fig. 7B and 7C). This observation could indicate
that GHRLOS may be a specific target in the development
of liver and other cancers.
Comparison of total GHRLOS and total GHRL 
expression
We examined the expression levels of the GHRL-GHRLOS
cis-natural antisense transcript (cis-NAT) pair via quantita-
tive real-time RT-PCR assays detecting total transcription
from the ghrelin gene (GHRL). As expected [31], the high-
est level of GHRL expression was found in the stomach
(data not shown), followed by the testis and pancreas
(Fig. 8). When comparing total ghrelin and GHRLOS RNA
expression in the stomach, GHRL was expressed at 2300
fold higher levels than GHRLOS, with GHRLOS expres-
sion almost undetectable (P < 0.001). The levels of GHR-
LOS expression were higher than GHRL in the thymus,
whole brain, the SW1353 chondrosarcoma cell line,
uterus and prostate. However, total GHRL  RNA levels
were higher than GHRLOS  in the pancreas and the
OVCAR-3 ovarian cancer cell line.
Discussion
Our study demonstrates that GHRLOS gives rise to long,
extensively spliced, mRNA-like, 5' capped and 3' polyade-
nylated transcripts suggesting that they are genuine prod-
ucts of RNA polymerase II mediated transcription [32].
We have shown that the GHRLOS gene gives rise to tran-
scripts 1.0 to 5.5 kb in size and has many broadly distrib-
uted transcription starts sites (TSSs) (Fig. 9). This includes
several TSSs in exon 1, TSSs overlapping the 3' UTR of
TATDN2 and evidence of transcription induced chimaeras
employing TSSs in the first exon of TATDN2. The ghrelin
locus, therefore, gives rise to many antisense transcripts
that are currently annotated as a single gene, GHRLOS. A
well-described example of such complex architecture is
the imprinted murine Gnas locus, which gives rise to mul-
tiple coding and non-coding sense and antisense tran-
scription units [33].
First reported in 1987 [34] and originally thought to be a
rarity, it has recently been established that promoters in 3'
untranslated regions (3' UTRs) are not uncommon and
may be independently transcribed and regulated from
their upstream "host gene" [35]. The ENCODE (ENCyclo-
pedia Of DNA Elements) consortium has recently demon-
strated that two-thirds of the loci in their dataset contain
new putative first exons, which frequently overlap
upstream genes [36]. However, it is currently not known
how promoters that overlap 3' UTRs are regulated and
coordinated [37]. We have demonstrated GHRLOS tran-
scription start sites in the 3' UTR of TATDN2 via RLM-
RACE. The sequence upstream of exon I of GHRLOS con-
tains no apparent TATA boxes (data not shown), indicat-
ing that GHRLOS has a broad type promoter, with many
potential transcription start sites in the 2.1 kb 3' UTR of
TATDN2. This may allow the transcription of numerous
tissue-specific and developmental stage-specific tran-
scripts [19]. In addition, multiple CAGE tags are present
in the 3' UTR of TATDN2, indicating that GHRLOS tran-
scripts initiate in this region.
Interestingly, we also report the joining of exons of the
neighbouring genes TATDN2 and GHRLOS. Similar chi-
maeric transcripts (not caused by chromosomal transloca-
tion) have been reported in lower eukaryotes [38,39], but
were until recently assumed to be relatively rare in mam-
mals [20,40-43]. It is not known how chimaeric tran-
scripts arise, but transcriptional read-through, followed
by canonical cis-splicing is the most likely mechanism
[40]. Alternatively, chimaeric transcripts could arise
through trans-splicing, but the existence of this mecha-
nism has not been well-established in mammals [44]. We,
therefore, suggest that the chimaeric TATDN2-GHRLOSBMC Molecular Biology 2008, 9:95 http://www.biomedcentral.com/1471-2199/9/95
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Strand-specific GHRLOS real-time RT-PCR Figure 7
Strand-specific GHRLOS real-time RT-PCR. (A) Strand-specific real-time RT-PCR approach to quantify GHRLOS expres-
sion. To select for RNA generated from the antisense strand, a linker sequence (LK) (not present in the genomic sequence of 
GHRLOS) is attached to a GHRLOS gene specific primer and employed in reverse transcription. The resulting cDNA is then 
combined in a real-time PCR, combining a gene-specific primer (GSP) and a primer containing the linker region from reverse 
transcription primer only. An internal TaqMan probe (depicted as a blue box) was employed to increase the specificity and sen-
sitivity of the assay. (B) Relative total GHRLOS expression in a range of human human tissues. (C) Relative total GHRLOS 
expression in human cell lines (U-937 non-Hodgkin's lymphoma, SW1353 chondrosarcoma, CaCo-2 colorectal adenocarci-
noma, SAOS-2 osteosarcoma, U-87 MG and U-251 MG glioblastoma, HEK293 human embryonic kidney and OVCAR-3 ovar-
ian cancer). Calculations of GHRLOS expression levels were performed using the standard curve method (correlating the 
threshold cycle number (CT values) and copy numbers of GHRLOS), and normalised to the expression of 18S ribosomal RNA. 
Each bar presents the mean ± standard deviation of duplicate reactions.BMC Molecular Biology 2008, 9:95 http://www.biomedcentral.com/1471-2199/9/95
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transcripts probably result from a single pre-mRNA, creat-
ing transcription-induced chimaeras (TICs) which are
spliced in cis [40]. The TATDN2-GHRLOS TIC which was
identified in the normal thymus harbours premature stop
codons (PTCs) and this is likely to result in nonsense-
mediated decay (NMD). NMD is an RNA surveillance
mechanism (present in eukaryotes) which targets mRNA
with premature stop codons that, if translated, encode
truncated proteins with dominant-negative or deleterious
gain-of function activities [21]. Whilst we are not aware of
any studies of the translated product of TATDN2 (TatD
DNase domain containing 2), TatD is a cytoplasmic pro-
tein that harbours magnesium-dependent DNase activity
in E. coli [45]. Proteins with a TatD domain, therefore,
belong to the large superfamily of metalloenzymes. This
suggests that the chimaeric transcripts may play a role in
auto-regulation of the TATDN2 protein product, which
we hypothesise is likely to be a DNase associated with
apoptosis. We speculate that TATDN2-GHRLOS chimae-
ras may be used to tightly regulate the programmed cell
death of T-cells by downregulating the translation of the
putative DNase TATDN2. Hillman and colleagues have
termed this system of auto-regulation, where alternative
splicing results in mRNA isoforms that are not translated,
regulated unproductive splicing and translation (RUST)
[46]. Interestingly, it has very recently been reported that
transcripts of the tumour suppressor protein E-cadherin
that result in non-sense mediated decay are upregulated in
gastric cancer, suggesting that NMD may also promote
disease [47].
We previously reported that GHRLOS completely overlaps
the ghrelin (GHRL) gene [8]. Here we also show that the
3' terminal exon 4 of GHRLOS is present on the opposite
(antisense) strand to a novel, 3' terminal SEC13 exon (Fig.
8). SEC13 is a protein that forms a part of the coat protein
complex II (COPII) [28]. COPII proteins are required for
the trafficking of nascent proteins from the endoplasmic
reticulum (ER) to the Golgi apparatus. It also plays a role
in the selection and concentration of cargo proteins for
transport [29]. SEC13 [28], therefore, has a core endocrine
function.  GHRLOS  overlaps a novel SEC13  variant,
SEC13-tentative (SEC13-T). SEC13-T may encode a 372
amino acid protein with a unique C-terminus. Future
Comparison of strand-specific GHRL and GHRLOS real-time RT-PCR Figure 8
Comparison of strand-specific GHRL and GHRLOS real-time RT-PCR. Relative total GHRL (sense, black) and GHRLOS 
(antisense, grey) RNA transcript expression levels in human tissues and cell lines. Calculations of RNA expression levels were 
performed using the standard curve method (correlating the threshold cycle number (CT values) and copy numbers of GHRL 
and GHRLOS) normalised to the expression of 18S ribosomal RNA. Each bar presents the mean ± standard deviation of dupli-
cate reactions.BMC Molecular Biology 2008, 9:95 http://www.biomedcentral.com/1471-2199/9/95
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studies are required to confirm the presence of full-length
transcripts and to elucidate the functional role of SEC13-
T protein. We suggest that transcription of SEC13-T may
have implications for COPII function in health and dis-
ease states. As GHRLOS overlaps the terminal exons of
both GHRL and SEC13-T, the GHRLOS natural antisense
transcripts may regulate one or both of these genes.
GHRLOS, a candidate non-coding RNA
Non-coding RNAs are frequently not conserved between
species, suggesting that they are either biological noise
(non-functional transcription), or that they have species
specific-functions. Species-specific non-coding transcripts
have been observed and there is strong evidence that non-
coding transcripts are functionally significant [48-52].
Interestingly it has recently been observed, using in silico
analysis, that even between closely related Drosophila spe-
cies non-coding RNAs are not conserved [53]. While the
number of protein coding genes in distant eukaryotes
(such as worms, mice, and humans) is approximately
equal, the relative amount of non-coding DNA increases
in proportion to eukaryotic complexity [54,55]. Mattick
and colleagues explain this paradox by hypothesising that
non-coding RNAs have evolved to enable the emergence
of organisms with increasingly complex higher levels
functions [55,56]. Our in silico analysis suggests that GHR-
LOS exons show very low sequence conservation in verte-
brate species. Furthermore, exon 4 of GHRLOS contains a
transposable element, a feature observed in many non-
coding RNAs [25-27].
Our bioinformatic studies indicate that GHRLOS does not
encode a protein and, therefore, is a non-coding RNA.
Taking into account the full-length sequence of GHRLOS,
the length of the open reading frames is very short. More-
over,  GHRLOS  RNAs are numerous (due to extensive
splicing), contain a large number of stop codons and there
is little nucleotide and putative amino acid conservation
between vertebrates, making it less likely that this gene
encodes proteins. Although it has been suggested that
many small peptides may be translated [57], the majority
of small peptides are processed from larger precursor pro-
teins, as is ghrelin itself which is processed from preprogh-
relin. Therefore, while it cannot be excluded that GHRLOS
encodes short ORFs (that are not conserved in the mouse)
it appears unlikely that GHRLOS  encodes biologically
active peptides.
We examined the GHRLOS  expression profile to
strengthen the hypothesis that it is a candidate non-cod-
ing RNA. It has been demonstrated that mammalian long
non-coding RNAs are expressed in a tissue-specific man-
ner, indicating that they are biologically significant
[50,58-61]. In both humans and mice, the major tissues
of non-coding expression are the complex organs; the
brain, testis, and thymus [50,61]. This also holds true in
Drosophila, where the majority of the candidate non-cod-
ing RNAs are expressed in the central nervous system [53].
Indeed, non-coding RNAs are emerging as important reg-
ulators of complex systems, such as the central nervous
system (brain) and intricate processes, including sperma-
togenesis in the testis [62-65]. We demonstrated high lev-
els of GHRLOS in the thymus, brain, testis, uterus, ovary
and thymus, while the expression levels in the stomach,
where GHRL is highly expressed [1], were almost undetec-
table. Our data demonstrate that GHRLOS is predomi-
nantly expressed in a limited number of tissues and cell
types, suggesting that these transcripts have physiological
functions in distinct cell types and tissues. Moreover, real-
time RT-PCR showed extremely low levels of GHRLOS in
the foetal and adult liver and high levels in the Hep G2
hepatocarcinoma cell line, suggesting that GHRLOS
Structure of genes at the GHRLOS locus Figure 9
Structure of genes at the GHRLOS locus. Structure of the human GHRLOS (top) and ghrelin (GHRL) (bottom) genes. 
Exons are shown as boxes and introns as lines. Genes on the positive DNA strand are displayed above the double-lines, while 
genes on the negative DNA strand are shown below. Arrows indicate transcription start sites of GHRLOS transcripts. Ghrelin 
(GHRL) exons are shown in grey, and GHRLOS in black. A novel exon of a putative SEC13 variant, SEC13-T is shown as white 
boxes. The terminal exon 8 of TATDN2 is indicated by a dotted line.BMC Molecular Biology 2008, 9:95 http://www.biomedcentral.com/1471-2199/9/95
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expression may be altered in liver cancer. Indeed, it has
recently been reported that non-coding RNA expression is
frequently altered in cancer [58,66]. This indicates that
non-coding RNAs may have specific functions in normal
cells. Much like protein-coding transcripts, ncRNAs may
act as tumour suppressors, or be upregulated in cancer
and act as oncogenes. An examination of GHRLOS expres-
sion in cancer would, therefore, be of great interest.
Here we have characterised the structure and organisation
of  GHRLOS, a ghrelin antisense gene, suggesting that
GHRLOS has multiple first exons. Therefore, it is possible
that GHRLOS could be a part of very large, continuous
ncRNA species in the 3p25 chromosomal region and
beyond. In the absence of hallmarks, such as large open
reading frames, mapping complex non-coding RNA genes
remains a complex task. For example, two RNAs in the
FMR1 locus, the cis-NAT ASFMR1 [67] and the non-cod-
ing RNA gene FMR4 (found just upstream of FMR1 [51])
may be one continuous RNA isoform [51].
What is the function of GHRLOS?
It is currently difficult and costly to determine the mecha-
nism of function of long non-coding RNAs. The roles of
non-coding RNAs are likely to be diverse, and there is
strong evidence that they play a role in regulating impor-
tant pathways. Many ncRNAs are expressed during devel-
opment, neural differentiation, during macrophage
activation and in cancer, indicating that they have key
functions in these processes [12,63,68]. Non-coding
RNAs have been found to play a role in the silencing of
overlapping genes in cis [69], in the silencing of distant
chromosome regions in trans [70], in nuclear trafficking
[71], apoptosis [51,72], promoter repression [73], and
can act as tumour suppressors [74]. Moreover, ncRNAs are
emerging as markers for complex human disease, includ-
ing lung cancer [75], heart disease [76], and a range of
other pathologies [68,77]. GHRLOS may also serve as a
host gene for snoRNA (small nucleolar RNAs) genes [78]
or GHRLOS RNA transcripts may be precursors for short
RNAs, such as micoRNAs [77], endogenous siRNAs
[79,80], piRNAs [81] and other novel, short non-coding
RNA species [82,83].
Although the understanding of natural antisense tran-
scripts (NATs) remains in its infancy, they have been asso-
ciated with a range of regulatory mechanisms that are not
necessarily mutually exclusive. This includes transcrip-
tional interference, RNA masking and dsRNA mediated
gene-silencing via direct interaction between the sense
and antisense transcripts [9,84,85].
While it is difficult to predict GHRLOS function, the fact
that all spliced GHRLOS  variants share exon 1, which
overlaps the 3' untranslated exon 4 of GHRL is striking.
Our findings suggest that GHRLOS functions as a non-
coding RNA. There are a few examples that suggest that
antisense transcripts are important in the regulation of
endocrine hormone receptors, including a thyroid hor-
mone receptor [86,87], and the luteinising hormone/cho-
riogonadotropin receptor [88] gene and in the regulation
of growth factors [89]. Interestingly, it has been recently
suggested that the invertebrate (insect) polypeptide hor-
mone allatostatin may be regulated by cis-NATs [90]. To
date, however the physiological and pathophysiological
roles of natural sense/antisense pairs have not been eluci-
dated for any vertebrate endocrine hormone. Further
studies are necessary to reveal the function and molecular
mechanisms regulating the candidate non-coding RNA
gene GHRLOS.
Conclusion
In the present study, we have characterised GHRLOS,
which gives rise to endogenous ghrelin natural antisense
transcripts. GHRLOS exhibits features which are common
to many non-coding RNA genes, including extensive splic-
ing, lack of significant and conserved open reading
frames, differential expression and lack of conservation in
vertebrates. Our data also reveal that GHRLOS contains
multiple first exons and that it overlaps both GHRL and a
novel SEC13 exon in the antisense direction, suggesting
that GHRLOS may have a role in regulating these genes.
Moreover, we report TATDN2-GHRLOS  chimaeras that
may function to regulate the translation of the putative
DNase TATDN2. Additional studies are underway to elu-
cidate the functions of GHRLOS and to investigate, in par-
ticular, its overlapping genomic arrangement with the
ghrelin gene. These studies may provide a new, physiolog-
ically relevant model system for investigating the roles of
antisense gene and non-coding RNA regulation and the
mechanisms involved, as well as establishing whether
GHRLOS RNAs may be useful markers for diagnosis and
prognosis of complex disease.
Methods
Bioinformatics
Multiple sequence alignments were generated using the
MUltiple sequence Local AligNment and conservation vis-
ualization tool (Mulan) [91]. Human [UCSC hg18],
chicken [UCSC galGal3], frog [UCSC xenTro2], opossum
[UCSC monDom4], mouse [UCSC mm9], rat [UCSC
rn4], dog [UCSC canFam2], rhesus macaque [UCSC
rheMac2], and chimpanzee [UCSC PanTro2] genomic
sequences were obtained via the Evolutionary Conserved
Regions (ECRs) Browser [92] and forwarded to Mulan to
generate a full local alignment of the GHRLOS  locus.
GHRLOS was annotated based on the exons sequenced in
this study.BMC Molecular Biology 2008, 9:95 http://www.biomedcentral.com/1471-2199/9/95
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To identify putative antisense exons and transcripts, we
examined the publicly available Affymetrix Human Exon
1.0 ST Array tissue panel dataset consisting of 11 tissues
(breast, cerebellum, heart, kidney, liver, muscle, pancreas,
prostate, spleen, testes, and thyroid) using the Affymetrix
All Exon track in the UCSC Genome Browser [93] and the
Integrated Genome Browser (IGB) from Affymetrix [94].
To locate transcription start sites in the putative first exons
of GHRLOS, CAGE (Cap Analysis of Gene Expression)
tags (deposited by the RIKEN consortium and its collabo-
rators) were obtained via the Genome Network Platform
Viewer [95]. We then recovered the RNA library informa-
tion for each CAGE tag starting site. Briefly, each CAGE tag
was individually queried against the 1.4 GB CAGE tag
sequencing file, (release date 13.11.2006) available on the
Genome Network Platform website using the UNIX grep
command [96].
The exon-intron-structure of ESTs and mRNA entries iden-
tified from BLAST searches, as well as sequenced PCR
amplicons obtained in this study, were analysed against
the human genome (NCBI release 35) using GMAP [14].
Presence of open reading frames was analysed by NCBI
ORF Finder [97], Fickett's TestCode [98,99] and ESTScan2
[100,101]. The presence of transposable elements in
GHRLOS sequence was examined using CENSOR v4.2.8
[22]. Protein domain analysis was performed using the
SMART database [102].
Cell culture and RNA extraction
The following cell lines (originally obtained from the
American Type Culture Collection/ATCC, Rockville, MD
unless specified) were cultured in their recommended
media: Prostate and/or prostate cancer derived cell lines
DU145 (ATCC HTB-81), RWPE-1 (ATCC CRL-11609),
RWPE-2 (ATCC CRL-11610), LNCaP (ATCC CRL-1740),
22Rv1 (ATCC CRL-2505) and PC3 (ATCC CRL-1435),
HEK293 human embryonic kidney (ATCC CRL-1573),
SAOS-2 osteosarcoma (ATCC HTB-85), Hep G2 hepato-
carcinoma (ATCC HB-8065), U-87 MG and U-251 MG
glioblastoma (ATCC HTB-14 and JCRB Cell Bank #
IFO50288, respectively), CaCo-2 colorectal adenocarci-
noma (ATCC HTB-37), SW1353 chondrosarcoma (ATCC
HTB-94), and OVCAR-3 ovarian cancer (ATCC HTB-161).
All cells were grown in T80 or T175 flasks (Nagle Nunc
International, Roskilde, Denmark) in 95% CO2 in a Sanyo
incubator at 37°C. Total RNA was harvested from cul-
tured cells at 70% confluence using TRIzol reagent (Invit-
rogen, Carlsbad, CA) according to the manufacturer's
instructions.
Human RNA samples
Tissue Total RNA was obtained from the stomach, pros-
tate (FirstChoice, Ambion, Austin, TX), foetal liver, adre-
nal gland, liver, trachea, salivary gland, spinal cord,
skeletal muscle, lung, placenta, bone marrow, kidney,
heart, whole brain, thyroid, cerebellum, uterus, foetal
brain, testis, thymus (Human total RNA Master Panel II,
Clontech, Mountain View, CA) and pancreas (Clontech).
5' and 3' RACE mapping of GHRLOS transcripts
To further characterise the 5' end of the putative ghrelin
antisense RNAs, 5' RACE was undertaken using FirstCh-
oice RLM-RACE-Ready human stomach cDNA (Ambion)
according to the manufacturer's instructions. The first
round PCR was performed with an adapter-specific sense
primer (5'adapter-out-F, Table 1) and an exon 2-specific
antisense primer (5'OS-out-R in Table 1). PCR product (1
μl) was used in a secondary, nested PCR with a gene spe-
cific primer in exon 2 (5'adapter-in-F and 5'OS-in-R, Table
1). PCRs were performed in a total reaction volume of 50
μl using 1 U of Platinum Taq Polymerase High Fidelity
(Invitrogen) according to the manufacturer's instructions.
For GHRLOS 3' RACE, human stomach and PC3 prostate
cancer cell line total RNA was reverse transcribed using
Transcriptor reverse transcriptase (Roche Applied Science
Applied Science, Penzberg, Germany) and 10 μM adapter
primer (3'-RACE-adapter, Table 1) from the FirstChoice
RLM-RACE Kit (Ambion). 3' RACE was performed with 2
μl of this cDNA. Two 3' RACE reactions were performed –
one combined an exon 4 GHRLOS-specific forward
primer and an adapter-specific reverse primer (3'4F and
3'2OR, Table 1), and the other used an adapter-specific
reverse primer and an exon 2-specific forward primer
3'2OR/F, Table 1). PCR products were then diluted and
used in a secondary, nested PCR with a gene-specific for-
ward and a reverse adapter primer (3'2IF/R, Table 1). PCR
products were purified using a High Pure PCR purification
kit (Roche Applied Science), cloned into pCR-XL-TOPO
(Invitrogen) or pGEM-T Easy (Promega, Madison, WI),
transformed into DH5α chemical competent cells (Invit-
rogen) and sequenced at the Australian Genome Research
Facility (AGRF, Brisbane, Australia) using BigDye III
(Applied Biosystems, AB, Foster City, CA).
Determination of GHRLOS transcription start and 
polyadenylation sites by Rolling Circle Amplification Rapid 
Amplification of cDNA Ends (RCA-RACE)
To simultaneously obtain the 5' and 3' ends of GHRLOS
transcripts, we employed Rolling Circle Amplification-
RACE (Rapid Amplification of cDNA Ends [103], an
improved inverse PCR approach. Briefly, 3 μg stomach,
prostate, RWPE-1 cell line and PC3 prostate cancer cell
line total RNA were reverse transcribed using 10 U of
Transcriptor reverse transcriptase (Roche Applied Science)
and 100 μM HPLC-purified 5'-end phosphorylated oligo
d(T)-adapter primer (Phospo-dT, Table 1) (Proligo, Boul-
der, CO) according to the manufacturer's instructions.BMC Molecular Biology 2008, 9:95 http://www.biomedcentral.com/1471-2199/9/95
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The single-stranded cDNA was purified using a High Pure
PCR purification kit (Roche Applied Science) and eluted
in 50 μl elution buffer (10 mM Tris-HCl, pH 8.5). Next, 25
μl purified linear cDNA was circularised using 100 U of
CircLigase (EPICENTRE Biotechnologies, Madison, WI)
and purified as before. After self-ligation, 15 μl circular
cDNA was added to a rolling circle amplification reaction
with 10 U of φ 29 DNA polymerase (NEB) and 10 μM
HPLC-purified random hexamer primers with two phos-
phothioate linkages on their 3'ends (Pthioate-hex, Table
1) (Proligo). Following a 21 h incubation at 30°C in a
waterbath, RCA-products were subjected to two rounds of
inverse PCR with 1 U of Platinum Taq HIFI polymerase
(Invitrogen), as per manufacturer's instructions. PCRs
were performed in a reaction volume of 50 μl using a PTC-
200 thermocycler (MJ Research, Waltham, MA). For the
first round amplification, the RCA reaction was diluted 1/
100 in water, and 1 μl used in an outer PCR with a forward
primer at the start of exon 4 and a reverse primer in exon
I (IPCR-out-F and IPCR-ALL-R, Table 1). After 35 cycles at
a 60°C annealing temperature, the outer PCR product was
diluted 100 times in water and 1 μl was used in a hemi-
nested PCR of 20 cycles, with annealing at 60°C (IPCR-in-
F and IPCR-ALL-R, Table 1). Amplification products were
eluted from agarose gels in 50 μl water overnight, reampli-
fied, cloned into pCR-XL-TOPO (Invitrogen), transformed
Table 1: Designations and sequences of oligonucleotides
Name Sequence (5'-3') GHRLOS Exon Ta (°C) PCR Cycles
5'2-out-F GATGGCGATGAATGAACACTG N/A
5'2-out-R AATCATCTCAGGAATACCTGGA 2 60 35
5'2-in-F ATGAATGAACACTGCGTTTGC N/A
5'2-in-R AAATGGAAGAGATGAGGCGC 2 61 35
Ex1-cRNA-F CATACAGTTTGAACATTTATTCGCCTCC 1
Ex1-cRNA-R CTAATACGACTCACTATAGGGAGACTCTCTCTAAGTTTAGAAGCGCTC
ATCTG
16 2 2 5
3'2OF GAGAGCGCCTCATCTCTTCC 2
3'2OR GCGAGCACAGAATTAATACGACTC N/A 63 35
3'2IF ATGATTTATTGGAGCTCAAAGC 2
3'2IR GAATTAATACGACTCACTATAGGT N/A 57 15
3'4 TACGGAACAGAGGAGAGATGC 4 60 35
3' -RACE-adapter GCGAGCACAGAATTAATACGACTCACTATAGGTTTTTTTTTTTTVN N/A N/A
IPCR-out-F AAATCCCACCTTTAGTCCCA 4 60 35
IPCR-in-F CTGCCACCTGAGTGTAGAC 4 60 20
IPCR-ALL-R CACAGGCTTGGAGACTTCC I
Pthioate-hex NNNNsNsN N/A 30 N/A
Phospho-dT P- GGCCACGCGTCGACTAGTAC(T)18 N/A 55 N/A
GHRL-Real-RT-LK CGACTGGAGCACGAGGACACTGAGCCAGAGAGCGCTTCTAAACTTA N/A N/A
GHRL-Real-F GCCCCAGCCGACAAGTG N/A 60 40
Ito4-F CATGGAAGTCTCCAAGCCTG I
Ito4-R CTGCTCTACTGCCTCAATGTC 4 63 34
GHRLOS-Real-RT-LK CGACTGGAGCACGAGGACACTGACAATCCTCCCTGAGGTTGATCT 4 N/A
GHRLOS-Real-F CATTGAGGCAGTAGAGCAGTTGA 4
LK CGACTGGAGCACGAGGACACTGA N/A 60 40
Ex4-TaqMan FAM-TGCCGAATGACCACCTACCCTGACTT- BHQ1 4
18S-Real-F TTCGGAACTGAGGCCATGAT N/A
18S-Real-R CGAACCTCCGACTTTCGTTCT N/A 60 40
F_CAGE GGGACTGCCTGTAATAGCAC I
R_CAGEout CACGACTGTTGTACAAGCTC 1 60 35
R_CAGEin GGAGGCGAATAAATGTTCAAACTG 1 61 30
ChiOut-F TGAAAGCCCAGAAGGAGGA N/A
ChiOut-R TCTAAGTTTAGAAGCGCTCATCTG 1 63 35
ChiIn-F CAGAAGGAGGACGATGTGG N/A
ChiIn-R CACGACTGTTGTACAAGCTC 1 62 30
UIS231-F ACAAGTTCAACGATGTGGTG N/A
UIS231-R CAAGTGTGAATAATAACCAAGCCC N/A 55 40
T7 promoter sequence in PCR primers is underlined. Linker sequence (LK) in the primer GHRLOS-Real-RT-LK and GHRL-Real-RT-LK is shown in 
bold. In primer 3' -RACE-adapter V denotes an A/G/C residue and N denotes A/G/C. Lowercase letters in primer Pthioate-hex denotes 
phosphothioate linkages. An uppercase P in primer Phospho-dT indicates that the synthetic oligonucleotide was 5' phosphorylated. Annealing 
temperatures (Ta) of oligonucleotides employed in PCR is shown. The GHRL or GHRLOS exon location of nucleotides are listed, while 
oligonucleotides spanning synthetic sequences (adapters and linkers) or genes other than GHRL and GHRLOS are denoted as N/A.BMC Molecular Biology 2008, 9:95 http://www.biomedcentral.com/1471-2199/9/95
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into One Shot MAX Efficiency DH5α-T1R chemically
competent cells (Invitrogen) and sequenced at the Aus-
tralian Genome Research Facility (AGRF, Brisbane, Aus-
tralia).
Northern blot hybridisation
Initially, a cRNA probe spanning exon I, II, 1 and 2 of
GHRLOS  was employed. Briefly, a 5' RACE clone in
pGEM-T Easy was linearised with SalI restriction enzyme
and a cRNA probe was synthesised using T7 RNA
polymerase and a digoxigenin (DIG) RNA labelling kit
(Roche Applied Science). Probe concentration was esti-
mated by dot blot comparison with digoxigenin-labelled
standards. 500 ng stomach poly(A)+ RNA (FirstChoice,
Ambion) was separated on a 1.2% formaldehyde gel and
blotted, as described previously [103]. Samples were elec-
trophoresed with 50 ng RNA Molecular Weight Marker II
(Roche Applied Science). The blot was hybridised to 50
ng/mL DIG-labelled cRNA probe overnight. Prehybridisa-
tion and hybridisation was performed with DIG-Easy Hyb
(Roche Applied Science) at 65°C. The membranes were
washed twice for 5 min at room temperature with 1 ×
Saline-Sodium Citrate (SSC), 0.1% sodium dodecyl sul-
fate (SDS) and then washed three times for 10 min at
65°C with 0.1 × SSC, 0.1% SDS. The membrane was then
reacted with an alkaline phosphatase (AP)-conjugated
anti-DIG antibody (Roche Applied Science). AP activity
was detected using a chemiluminescence method using
CDP-Star (Roche Applied Science).
A second cRNA probe, which spanned exon 1 (which is
common to all known GHRLOS mRNA isoforms) was
synthesised from 100 ng human stomach genomic DNA
(BioChain, Hayward, CA) using the PCR method [104]
(Ex1-cRNA-F/R, Table 1). The PCR product was purified
using a High Pure PCR Product Purification Kit (Roche
Applied Science) and the DIG-labelled cRNA probe syn-
thesised and quantified as detailed above. A multi-tissue
membrane containing poly(A)+ RNA from 12 human tis-
sues (brain, duodenum, oesophagus, pancreas, PBL/leu-
kocytes, prostate, salivary gland, testis, thymus, thyroid,
urinary bladder and uterus) was purchased from OriGene
(Rockville, MD). Prehybridisation and hybridisation were
performed as described above, except that ULTRAhyb
Ultrasensitive Hybridization Buffer (Ambion) was used
instead of DIG-Easy Hyb (Roche Applied Science). Equiv-
alent loading between tissues on the blot was determined
by rehybridising with 20 ng/mL DIG-labelled β-actin
cRNA probe (Roche Applied Science).
Isolation of alternatively spliced GHRLOS mRNAs via 
non-quantitative RT-PCR
For non-quantitative RT-PCR analysis of GHRLOS splic-
ing, RT-PCRs were performed with a forward primer in a
region common to the 5' terminal exon Ia/b and a reverse
primer in the 3' terminal exon 4 of GHRLOS (Ito4-F/R,
Table 1). cDNA was synthesised in a final volume of 20 μl
from 3 μg total RNA from tissues and cell lines using 10 U
of Transcriptor reverse transcriptase (Roche Applied Sci-
ence), 20 U of RNasin Plus RNase Inhibitor (Promega)
and a 3' RACE adapter primer (3'-RACE-adapter, Table 1)
at 55°C according to the manufacturer's instructions. PCR
amplicons from the stomach, prostate, foetal brain, heart,
thymus, testis, and pancreas were purified, sub-cloned
and sequenced as described above.
Long-range RT-PCR to detect putative chimaeric 
TATDN2-GHRLOS transcripts
To detect long, chimaeric transcripts, we employed RT-
PCR with a forward primer in exon 2 of TATDN2
(ChiOut-F, Table 1) and a reverse primer in exon 1 of
GHRLOS (ChiOut-R, Table 1). PCR was carried out with 1
U of Platinum Taq HIFI polymerase (Invitrogen) as per
manufacturer's instructions, extending at 68°C for 2.5
minutes per cycle. cDNA was synthesised as above in a
final volume of 20 μl from 2 μg total RNA, from the Hep
G2 hepatocarcinoma cell line, CaCo-2 colorectal adeno-
carcinoma cell line, OVCAR-3 ovarian cancer cell line, and
from a range of normal tissues (testis, prostate, pancreas,
thymus, and foetal brain). RT-PCR products were sub-
cloned and sequenced as described above.
CAGE-aided cDNA primer walking
To determine if the identified upstream CAGE tag starting
sites transcribe exons that belong to GHRLOS, we
employed RT-PCR using a forward primer designed to the
region immediately after a CAGE cluster in the ~2 kb 3'
untranslated region of the adjacent gene TATDN2 (TSS ID
T03F009D1927) and a reverse primer in exon 1, an exon
which is common to all known GHRLOS  variants
(F_CAGE and R_CAGEout in Table 1, respectively). cDNA
was synthesised in a final volume of 20 μl from 2 μg total
RNA, from the Hep G2 hepatocarcinoma cell line and the
thymus and foetal brain, using 10 units Transcriptor
reverse transcriptase (Roche Applied Science), 20 U of
RNasin Plus RNase Inhibitor (Promega) and oligo(dT)18
primers (Proligo) according to the manufacturer's instruc-
tions. The cDNAs were subjected to 35 cycles of PCR with
a two-minute extension time per cycle, and then diluted
1/100 in water and subjected to a hemi-nested 30-cycle
PCR with a nested primer in exon 1 (R_CAGEin, Table 1).
PCRs were performed in a total reaction volume of 50 μl
using 10 U of Platinum Taq  Polymerase High Fidelity
(Invitrogen) according to the manufacturer's instructions.
Entire PCR products were purified using the High Pure
PCR Product Purification Kit (Roche Applied Science),
subcloned into pCR-XL-TOPO  (Invitrogen) and trans-
formed into One Shot MAX Efficiency DH5α-T1R chemi-
cal competent cells (Invitrogen). Insert-positive, purified
clones were sequenced by the Australian GenomeBMC Molecular Biology 2008, 9:95 http://www.biomedcentral.com/1471-2199/9/95
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Research Facility (AGRF, Brisbane, Australia) using the AB
PRISM BigDye Terminator Cycle Sequencing Kit v3.1 pro-
tocol (AB).
Identification of novel SEC13 exon
To verify the presence of a novel SEC13 exon identified in
a brain tumour EST [GenBank:BF931280], cDNAs reverse
transcribed with an oligo(dT) primer (as described above)
were challenged by RT-PCR with primers in exon 8 of
SEC13 and a reverse primer in the novel exon (231-F/R,
Table 1, respectively).
Strand-specific, quantitative real-time RT-PCR
To allow strand-specific and RNA-specific amplification
[105-107] of GHRLOS  transcripts, reverse transcription
was performed using a gene-specific primer in exon 4 with
a linker (LK) [107] sequence attached to the 5' end of the
primer (GHRLOS-Real-RT-LK, Table 1). cDNA was gener-
ated from 1 μg total RNA using 40 U of AMV reverse tran-
scriptase (Roche Applied Science) at 42°C, according to
the manufacturer's instructions. The strand-specific, real-
time RT-PCR was performed with an exon 4 specific for-
ward primer, a reverse primer with the LK sequence only
(GHRLOS-Real-F and LK, Table 1) and a TaqMan probe
(Ex4-TaqMan, Table 1). To detect sense GHRL transcripts,
we employed a strand-specific RT-PCR approach, with a
reverse transcription primer spanning the 3' terminal exon
4 of the ghrelin gene (GHRLex4_RT_LK, Table 1) followed
by PCR with an exon 4 specific forward primer
(GHRLex4_F, Table 1) and a linker-specific reverse
primer. (LK, Table 1). The relative quantification of GHR-
LOS and GHRL transcripts was estimated by direct nor-
malisation to the threshold cycle (CT) of the
housekeeping gene, 18S ribosomal RNA (18S-Real-F/R,
Table 1). 18S PCRs were used to normalise real-time data.
As reported for GAPDH [107], 18S RNAs self-primes effi-
ciently in reverse transcription reactions without the addi-
tion of random or gene-specific primers. All primers were
designed using the Primer Express version 2.0 software
(AB).
PCRs were performed in a total reaction volume of 20 μl
using Platinum Quantitative PCR SuperMix-UDG w/ROX
(Invitrogen) for GHRLOS, while GHRL and the house-
keeping gene 18S ribosomal RNA were amplified using 2
× SYBR green master mix (AB). Controls included the use
of cDNA, which was reverse transcribed using random
hexamers as primers, as well as the reverse transcription of
RNA in the absence of primer. Real-time RT-PCR was per-
formed using the AB 7000 sequence detection system
(AB) and data analysed using the absolute standard curve
method (User Bulletin #2, AB) to determine expression
levels in a range of tissues and cell lines. Briefly, we calcu-
lated values from duplicate reactions for each sample
from standards, which were constructed from PCR prod-
ucts. Statistical significance was determined using the Stu-
dent's t-test and, where applicable, one-way analysis of
variance (ANOVA) with Tukey post-hoc analysis. P-values
of < 0.05 were considered to be statistically significant.
Data are represented as mean ± standard deviation (S.D.).
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Expression) (*), are indicated, and the exact transcription start site nucle-
otides are underlined and in bold. For comparison, the sequence of the ref-
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Ethidium bromide stained agarose gel electrophoresis of GHRLOS exon I 
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